Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

127.46USD
25 Jul 2016
Change (% chg)

$1.66 (+1.32%)
Prev Close
$125.80
Open
$125.71
Day's High
$127.93
Day's Low
$125.34
Volume
1,382,218
Avg. Vol
1,838,200
52-wk High
$205.29
52-wk Low
$110.56

ALXN.O

Chart for ALXN.O

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products... (more)

Overall

Beta: 1.00
Market Cap(Mil.): $28,181.74
Shares Outstanding(Mil.): 224.02
Dividend: --
Yield (%): --

Financials

  ALXN.O Industry Sector
P/E (TTM): 175.24 36.15 37.05
EPS (TTM): 0.72 -- --
ROI: 1.81 15.11 14.35
ROE: 2.51 16.17 15.56

U.S. RESEARCH ROUNDUP-D.R. Horton, Humana, Chicago Bridge & Iron

July 22 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adeptus Health, Chipotle Mexican Grill and Yadkin Financial, on Friday. HIGHLIGHTS * Chicago Bridge & Iron Co : Baird cuts to neutral * D.R. Horton Inc : BofA Merrill cuts to neutral from buy * Humana Inc : Wolfe Research raises to outperform * Community Bank System Inc : Sandler O'Neill cuts to

Jul 22 2016

BRIEF-Alexion presents new SBC-103 data in patients with MPS iiiB

* Alexion presents new SBC-103 (Rhnaglu enzyme) phase 1/2 data on brain MRI and neurocognitive assessments in patients with mucopolysaccharidosis iiib (MPS IIIB)

Jul 14 2016

BRIEF-Alexion Pharmaceuticals announces data from phase 1/2 study of ALXN1210

* Late-Breaking data presented at EHA: all patients with pnh treated with once-monthly dosing of ALXN1210 in phase 1/2 study exhibit rapid and sustained reductions in ldhSays announced today that interim data were presented from a phase 1/2 study of ALXN1210

Jun 10 2016

US STOCKS-S&P edges closer to record high; energy shares lead

* Dow up 0.1 pct, S&P up 0.1 pct, Nasdaq down 0.1 pct (Updates to close)

Jun 07 2016

US STOCKS-S&P edges closer to record high; energy shares lead

* Dow up 0.3 pct, S&P up 0.3 pct, Nasdaq down 0.04 pct (Updates to late afternoon)

Jun 07 2016

Alexion shares slump as drug misses goal in late-stage trial

Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial.

Jun 06 2016

UPDATE 1-Alexion shares slump as drug misses goal in late-stage trial

June 6 Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial.

Jun 06 2016

Alexion drug misses goal in late-stage trial

June 6 Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial, sending its shares down 9 percent in extended trade.

Jun 06 2016

BRIEF-Alexion announces topline results from Phase 3 regain study of eculizumab

* Alexion announces topline results from Phase 3 regain study of eculizumab (soliris) in patients with refractory generalized myasthenia gravis (GMG)

Jun 06 2016

BRIEF-Alexion says CEO David Hallal's 2015 compensation was $14.7 mln

* Says CFO Vikas Sinha FY 2015 total compensation $4.7 million versus $7 million in FY 2014 - sec filing

Mar 31 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.